Evidence map›Paper›PMID 28964784›Full record

ArticleCancer letters2017

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Teresa Di Desidero, Alessandro Antonelli, Paola Orlandi, Silvia Martina Ferrari, Anna Fioravanti, Greta Alì, Gabriella Fontanini, Fulvio Basolo, Giulio Francia, Guido Bocci

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy.Frontiers in cellular and infection microbiology · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. The pharmacokinetic interaction between irinotecan and sunitinib.Cancer chemotherapy and pharmacology · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Teresa Di DesideroDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy.
Alessandro AntonelliDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy.
Paola OrlandiDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy.
Silvia Martina FerrariDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy.
Anna FioravantiDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy.
Greta AlìDipartimento di Patologia Chirurgica, Medica, Molecolare e Dell'Area Critica, University of Pisa, Pisa, I-56126 Pisa, Italy.
Gabriella FontaniniDipartimento di Patologia Chirurgica, Medica, Molecolare e Dell'Area Critica, University of Pisa, Pisa, I-56126 Pisa, Italy.
Fulvio BasoloDipartimento di Patologia Chirurgica, Medica, Molecolare e Dell'Area Critica, University of Pisa, Pisa, I-56126 Pisa, Italy.
Giulio FranciaBorder Biomedical Research Center, University of Texas at El Paso, Texas, USA.
Guido BocciDipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, I-56126 Pisa, Italy. Electronic address: guido.bocci@med.unipi.it.
University of Pisa · ITThe University of Texas at El Paso · US

Funding

The role of breast cancer organ specific metastasis on the therapeutic impact of anti-cancer drugsSC1GM136630 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI FRANCIA, GIULIO · 2020 to 2023
$1.5M
NIGMS NIH HHS SC1 GM136630
6 · The paper itself

Abstract

The identification of new therapeutic strategies is urgently needed for the management of patients affected by anaplastic thyroid cancer (ATC) due to their short survival and poor prognosis. Aim of the study was to determine the activity of the combination irinotecan/sunitinib on ATC cell growth in vitro and the antitumor effects in vivo. Proliferation assays were performed for 72 h on ATC cell lines exposed to the combination of SN-38, the active metabolite of irinotecan, and sunitinib. The simultaneous combination of sunitinib and SN-38, quantified by the combination index, determined a high synergism on ATC cells, increasing the intracellular concentrations of SN-38. Moreover, the synergistic combination greatly decreases the gene expression and the protein levels of vascular endothelial growth factor, colony stimulating factor 1 and ATP-binding cassette transporter G2 in ATC cells. A significant in vivo antitumor effect was observed in ATC xenografts with the simultaneous combination of irinotecan and sunitinib if compared to monotherapy. The simultaneous combination of irinotecan and sunitinib, in vitro and in vivo demonstrated a significant, synergistic ATC antitumor activity, suggesting a possible and rapid translation of this schedule into the clinics.

Indexed as

AgedAnimalsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsApoptosisCamptothecinCell Line, TumorDrug SynergismFemaleHumansIndolesIrinotecanMaleMiceMice, NudePyrrolesAntineoplastic Agents, PhytogenicCamptothecinIndolesIrinotecanPyrrolesSunitinibAnaplastic thyroid cancerIrinotecanSunitinibSynergismTumor xenografts

Identifiers

PMID28964784
PMCPMC8022336
OpenAlexW2760378413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.